Please assess the completion status of the following clinical trial:

Trial Title: Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be willing and able to give informed consent to participate in the trial and to adhere to the procedures stated in the protocol~* ≥18 years of age~* Patient is admitted to a hospital (max. 72 hours prior to randomization) due to COVID-19 and has a positive SARS-CoV-2 PCR test~* Clinical symptoms indicative of moderate or severe illness (corresponding to score 5 or 6 on the WHO 10-point clinical progression scale) with COVID 19 prior to trial treatment~* Patient agrees to not participate in another clinical trial from screening until day 56~Exclusion Criteria:~* Patient is moribund or has an estimated life expectancy \<1 month (e.g., terminal cancer, etc.)~* Patient is anticipated to be discharged from hospital within 48 hours~* Patient requires anti-inflammatory medicines beyond SoC (SoC are drugs that are approved for treatment of COVID-19 as well as medicines that have been recommended in treatment guidelines of national health authorities and/or professional organization)~* Patient requires invasive mechanical ventilation~* Patient is known to have active tuberculosis~* Patient is known to have hereditary fructose intolerance.~* Patient is known to have co-infection with Influenza viruses or other viral respiratory infections (respiratory syncytial virus \[RSV\], parainfluenza viruses, respiratory adenoviruses).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care + Asunercept 100 mg (Type: EXPERIMENTAL): None
- Standard of Care + Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).